Back to News
Market Impact: 0.45
Nano Cap Lisata Therapeutics Bolsters Cardioendocrine Pipeline Strategy
Source: benzinga.com
M&A & RestructuringPrivate Markets & VentureHealthcare & Biotech
Lisata Therapeutics acquired clinical-stage biotech Marea Therapeutics and completed an oversubscribed $225 million private-placement financing. The transaction materially strengthens Lisata's capital base and expands its clinical-stage biotechnology platform, with likely positive implications for the company's development pipeline.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
moderately positive
Sentiment Score
0.60
Ticker Sentiment
LSTA0.85
More News
- Lisata Therapeutics acquires Marea Therapeutics, secures $225 million private placement
- California AG Says Paramount-WBD Merger Would Hurt the State
- California AG Bonta on Paramount-Warner Bros., Meta and AI
- Crusoe raises $3.9B to build massive data centers and small modular “AI factories”
- Halozyme prices $1.3 billion convertible notes offering
- Jana Partners pushes Cooper to replace CEO, weigh asset sales- WSJ